Australian Cancer Drug Licensed in $730M Deal
MELBOURNE, Australia, February 9, 2016 (ENS) – A promising new cancer drug, developed in Australia by the Cancer Therapeutics CRC (CTx), has been licensed to U.S. pharmaceutical company Merck in a deal worth US$730 million. […]